Shanghai, April 7, 2016 -- Yaoming Biology, a wholly-owned subsidiary of Wuming Kangde, and Beihai Kangcheng, a Chinese innovative pharmaceutical technology enterprise, signed a strategy today
Shanghai, April 7, 2016-- Yaoming Bio, a wholly-owned subsidiary of Wuming Kangde, and Beihai Kangcheng, a Chinese innovative pharmaceutical technology enterprise, today signed a strategic cooperation agreement. Yaoming Bio will provide Beihai Kangcheng with technical services such as preclinical pharmaceutical research, process transfer, optimization and mass production of the innovative antibody fusion protein drug CAN-008, which is used to target glioblastoma in China. At the same time, Beihai Kangcheng announced that the company had successfully submitted the application for clinical research of new drugs (IND) of CAN-008 to the drug regulatory authority in Taiwan.
Glioblastoma cerebri (GBM) is one of the tumors with high mortality * and poor prognosis *. The 5-year mortality rate is second only to pancreatic cancer and lung cancer in general tumors. Currently, there are few clinical options for the treatment of glioblastoma. To meet the clinical needs of Chinese patients, Beihai Kangcheng cooperated with APOGENIX in July 2015 GmbH has reached a patent licensing cooperation agreement and obtained the * * right to research, develop, produce and commercialize CAN-008 in mainland China, Hong Kong and Macao. The scope of this cooperation agreement was recently extended to Taiwan.
"Beihai Kangcheng's successful application for IND in Taiwan marks that we are about to become a biomedical company in the clinical stage." Dr. Xue Qun, chairman and executive officer of Beihai Kangcheng, said, "We are also very happy to cooperate with Yaoming Bio to develop and produce CAN-008 for the Chinese market. Both parties will carry out the preclinical research of the drug in mainland China as soon as possible to prepare for submitting the IND application to the * * Food and Drug Administration (CFDA). "
"Yaoming Biotech congratulates Beihai Kangcheng on rapidly becoming an innovative bio pharmaceutical company with clinical stage products," said Dr. Chen Zhisheng, executive officer of Yaoming Biotech * *, "We are very happy to cooperate closely with Beihai Kangcheng to produce this innovative antibody fusion protein drug for the Chinese market through the biological drug R&D and production platform of Yaoming Biotech World * *. Such innovative cooperation is expected to bring more life-saving biological innovative drugs that people can buy and can afford to buy to the Chinese market. "
The Chinese government has recently launched a series of reform measures in the drug review and approval system, and has launched the pilot work of the drug marketing authorization holder (MAH) system in several provinces across the country, which will effectively improve the research and development of innovative drugs in China and optimize the allocation of drug resources. WuXi AppTec, as a platform for innovative companies to realize their dreams of new drug research and development, is expected to provide more innovative biomedical technology companies at home and abroad with * * level integrated biopharmaceutical research and development and production services in the future, accelerate the listing process of innovative biopharmaceuticals in China, and benefit the vast number of patients.
About Beihai Kangcheng
Beihai Kangcheng is an innovative pharmaceutical technology enterprise headquartered in Beijing, China. By connecting the world's * large life high-tech pharmaceutical product line with the global application market with * fast growth and * large potential, it aims to accelerate the marketization of high-end, * * medical products in China and Asia. The core competitiveness of Beihai Kangcheng is not only reflected in the consultants and management team of *******. Compared with other enterprises in the industry, Beihai Kangcheng's ability to select, evaluate and obtain high-quality projects, project implementation and management capabilities, and scientific research strength of clinical development all show its superior advantages. For more information, visit:
About WuXi AppTec
WuXi AppTec is an open capability and technology platform company of * * * *, which provides all-round integrated laboratory R&D and production services from drug discovery, development to marketization for global pharmaceutical, biotechnology, medical devices and other fields. With the purpose of taking research as the first task and taking customers as the center, WuXi AppTec helps global customers shorten the R&D cycle of drugs and medical devices and reduce R&D costs through a cost-effective and efficient service platform to benefit global patients. For details, please visit the company's website:
About Yaoming Biology
As a wholly-owned subsidiary of WuXi AppTec, WuMing Biotech focuses on building an open and integrated capability and technology platform, providing comprehensive R&D and production services for global biopharmaceutical companies and biotechnology companies, and helping anyone and any company realize the dream of biopharmaceutical R&D. As a * * enterprise engaged in cooperative research, development and production (CDMO) of biopharmaceuticals, Yaoming Biologicals is committed to providing professional one-stop biopharmaceutical research, development and production services to global customers, accelerating the research and development process of global biopharmaceuticals from innovative ideas to commercial production, reducing research and development costs and benefiting patients.
(Reprinted/Internet information)
